321 related articles for article (PubMed ID: 18285713)
1. Clinical outcome of HIV-infected antiretroviral-naive patients with discordant immunologic and virologic responses to highly active antiretroviral therapy.
Tan R; Westfall AO; Willig JH; Mugavero MJ; Saag MS; Kaslow RA; Kempf MC
J Acquir Immune Defic Syndr; 2008 Apr; 47(5):553-8. PubMed ID: 18285713
[TBL] [Abstract][Full Text] [Related]
2. Discordant immunologic and virologic responses to highly active antiretroviral therapy are associated with increased mortality and poor adherence to therapy.
Moore DM; Hogg RS; Yip B; Wood E; Tyndall M; Braitstein P; Montaner JS
J Acquir Immune Defic Syndr; 2005 Nov; 40(3):288-93. PubMed ID: 16249702
[TBL] [Abstract][Full Text] [Related]
3. Discordant responses on starting highly active antiretroviral therapy: suboptimal CD4 increases despite early viral suppression in the UK Collaborative HIV Cohort (UK CHIC) Study.
Gilson RJ; Man SL; Copas A; Rider A; Forsyth S; Hill T; Bansi L; Porter K; Gazzard B; Orkin C; Pillay D; Schwenk A; Johnson M; Easterbook P; Walsh J; Fisher M; Leen C; Anderson J; Sabin CA;
HIV Med; 2010 Feb; 11(2):152-60. PubMed ID: 19732175
[TBL] [Abstract][Full Text] [Related]
4. Clinical outcome of patients with HIV-1 infection according to immunologic and virologic response after 6 months of highly active antiretroviral therapy.
Grabar S; Le Moing V; Goujard C; Leport C; Kazatchkine MD; Costagliola D; Weiss L
Ann Intern Med; 2000 Sep; 133(6):401-10. PubMed ID: 10975957
[TBL] [Abstract][Full Text] [Related]
5. Discordant responses to potent antiretroviral treatment in previously naive HIV-1-infected adults initiating treatment in resource-constrained countries: the antiretroviral therapy in low-income countries (ART-LINC) collaboration.
Tuboi SH; Brinkhof MW; Egger M; Stone RA; Braitstein P; Nash D; Sprinz E; Dabis F; Harrison LH; Schechter M
J Acquir Immune Defic Syndr; 2007 May; 45(1):52-9. PubMed ID: 17460471
[TBL] [Abstract][Full Text] [Related]
6. Treatment with highly active antiretroviral therapy in human immunodeficiency virus type 1-infected children is associated with a sustained effect on growth.
Verweel G; van Rossum AM; Hartwig NG; Wolfs TF; Scherpbier HJ; de Groot R
Pediatrics; 2002 Feb; 109(2):E25. PubMed ID: 11826235
[TBL] [Abstract][Full Text] [Related]
7. Psychiatric illness and virologic response in patients initiating highly active antiretroviral therapy.
Pence BW; Miller WC; Gaynes BN; Eron JJ
J Acquir Immune Defic Syndr; 2007 Feb; 44(2):159-66. PubMed ID: 17146374
[TBL] [Abstract][Full Text] [Related]
8. Measures of site resourcing predict virologic suppression, immunologic response and HIV disease progression following highly active antiretroviral therapy (HAART) in the TREAT Asia HIV Observational Database (TAHOD).
Oyomopito R; Lee MP; Phanuphak P; Lim PL; Ditangco R; Zhou J; Sirisanthana T; Chen YM; Pujari S; Kumarasamy N; Sungkanuparph S; Lee CK; Kamarulzaman A; Oka S; Zhang FJ; Mean CV; Merati T; Tau G; Smith J; Li PC;
HIV Med; 2010 Sep; 11(8):519-29. PubMed ID: 20345881
[TBL] [Abstract][Full Text] [Related]
9. Role of hepatitis C virus (HCV) viremia and HCV genotype in the immune recovery from highly active antiretroviral therapy in a cohort of antiretroviral-naive HIV-infected individuals.
Antonucci G; Girardi E; Cozzi-Lepri A; Capobianchi MR; De Luca A; Puoti M; Petrelli E; Carnevale G; Rizzardini G; Grossi PA; Viganò P; Moioli MC; Carletti F; Solmone M; Ippolito G; Monforte AD; ;
Clin Infect Dis; 2005 Jun; 40(12):e101-9. PubMed ID: 15909251
[TBL] [Abstract][Full Text] [Related]
10. Response to highly active antiretroviral therapy according to duration of HIV infection.
Pezzotti P; Pappagallo M; Phillips AN; Boros S; Valdarchi C; Sinicco A; Zaccarelli M; Rezza G;
J Acquir Immune Defic Syndr; 2001 Apr; 26(5):473-9. PubMed ID: 11391168
[TBL] [Abstract][Full Text] [Related]
11. Factors associated with 10 years of continuous viral load suppression on HAART.
Bello KJ; Mesner O; O'Bryan TA; Won SH; Lalani T; Ganesan A; Agan BK; Okulicz JF
BMC Infect Dis; 2016 Jul; 16():351. PubMed ID: 27449671
[TBL] [Abstract][Full Text] [Related]
12. Effect of HIV-1 subtype on virologic and immunologic response to starting highly active antiretroviral therapy.
Geretti AM; Harrison L; Green H; Sabin C; Hill T; Fearnhill E; Pillay D; Dunn D;
Clin Infect Dis; 2009 May; 48(9):1296-305. PubMed ID: 19331585
[TBL] [Abstract][Full Text] [Related]
13. Immunologic and virologic consequences of temporary antiretroviral treatment interruption in clinical practice.
Chen RY; Westfall AO; Raper JL; Cloud GA; Chatham AK; Acosta EP; Pham SV; Tolson JM; Heudebert GR; Saag MS
AIDS Res Hum Retroviruses; 2002 Sep; 18(13):909-16. PubMed ID: 12230934
[TBL] [Abstract][Full Text] [Related]
14. Mortality associated with discordant responses to antiretroviral therapy in resource-constrained settings.
Tuboi SH; Pacheco AG; Harrison LH; Stone RA; May M; Brinkhof MW; Dabis F; Egger M; Nash D; Bangsberg D; Braitstein P; Yiannoutsos CT; Wood R; Sprinz E; Schechter M;
J Acquir Immune Defic Syndr; 2010 Jan; 53(1):70-7. PubMed ID: 20035163
[TBL] [Abstract][Full Text] [Related]
15. Diagnostic accuracy of CD4 cell count increase for virologic response after initiating highly active antiretroviral therapy.
Bisson GP; Gross R; Strom JB; Rollins C; Bellamy S; Weinstein R; Friedman H; Dickinson D; Frank I; Strom BL; Gaolathe T; Ndwapi N
AIDS; 2006 Aug; 20(12):1613-9. PubMed ID: 16868442
[TBL] [Abstract][Full Text] [Related]
16. Prognostic factors of combined viral load and CD4+ cell count responses under triple antiretroviral therapy, Aquitaine cohort, 1996-1998.
Marimoutou C; Chêne G; Mercié P; Neau D; Farbos S; Morlat P; Ceccaldi J; Dabis F;
J Acquir Immune Defic Syndr; 2001 Jun; 27(2):161-7. PubMed ID: 11404538
[TBL] [Abstract][Full Text] [Related]
17. Effect of Pregnancy on Response to Antiretroviral Therapy in HIV-Infected African Women.
Kourtis AP; Wiener J; King CC; Heffron R; Mugo NR; Nanda K; Pyra M; Donnell D; Celum C; Lingappa JR; Baeten JM;
J Acquir Immune Defic Syndr; 2017 Jan; 74(1):38-43. PubMed ID: 27787340
[TBL] [Abstract][Full Text] [Related]
18. Clinical outcome of HIV-infected patients with sustained virologic response to antiretroviral therapy: long-term follow-up of a multicenter cohort.
Gutierrez F; Padilla S; Masiá M; Iribarren JA; Moreno S; Viciana P; Muñoz L; Gómez Sirvent JL; Vidal F; López-Aldeguer J; Blanco JR; Leal M; Rodríguez-Arenas MA; Perez Hoyos S;
PLoS One; 2006 Dec; 1(1):e89. PubMed ID: 17183720
[TBL] [Abstract][Full Text] [Related]
19. Differential impact of adherence on long-term treatment response among naive HIV-infected individuals.
Lima VD; Harrigan R; Murray M; Moore DM; Wood E; Hogg RS; Montaner JS
AIDS; 2008 Nov; 22(17):2371-80. PubMed ID: 18981777
[TBL] [Abstract][Full Text] [Related]
20. Switching HIV treatment in adults based on CD4 count versus viral load monitoring: a randomized, non-inferiority trial in Thailand.
Jourdain G; Le Cœur S; Ngo-Giang-Huong N; Traisathit P; Cressey TR; Fregonese F; Leurent B; Collins IJ; Techapornroong M; Banchongkit S; Buranabanjasatean S; Halue G; Nilmanat A; Luekamlung N; Klinbuayaem V; Chutanunta A; Kantipong P; Bowonwatanuwong C; Lertkoonalak R; Leenasirimakul P; Tansuphasawasdikul S; Sang-A-Gad P; Pathipvanich P; Thongbuaban S; Wittayapraparat P; Eiamsirikit N; Buranawanitchakorn Y; Yutthakasemsunt N; Winiyakul N; Decker L; Barbier S; Koetsawang S; Sirirungsi W; McIntosh K; Thanprasertsuk S; Lallemant M;
PLoS Med; 2013 Aug; 10(8):e1001494. PubMed ID: 23940461
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
